These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 17604870)
1. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. Arnold MM; Gorman EM; Schieber LJ; Munson EJ; Berkland C J Control Release; 2007 Aug; 121(1-2):100-9. PubMed ID: 17604870 [TBL] [Abstract][Full Text] [Related]
2. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245 [TBL] [Abstract][Full Text] [Related]
3. Formulation of porous poly(lactic-co-glycolic acid) microparticles by electrospray deposition method for controlled drug release. Hao S; Wang Y; Wang B; Deng J; Zhu L; Cao Y Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():113-9. PubMed ID: 24863206 [TBL] [Abstract][Full Text] [Related]
4. Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization. Ni R; Muenster U; Zhao J; Zhang L; Becker-Pelster EM; Rosenbruch M; Mao S J Control Release; 2017 Mar; 249():11-22. PubMed ID: 28109773 [TBL] [Abstract][Full Text] [Related]
5. Structured Biodegradable Polymeric Microparticles for Drug Delivery Produced Using Flow Focusing Glass Microfluidic Devices. Ekanem EE; Nabavi SA; Vladisavljević GT; Gu S ACS Appl Mater Interfaces; 2015 Oct; 7(41):23132-43. PubMed ID: 26423218 [TBL] [Abstract][Full Text] [Related]
6. Porous PLGA microparticles prepared with nanosized/micronized sugar particles as porogens. Zhang C; Bodmeier R Int J Pharm; 2024 Jul; 660():124329. PubMed ID: 38857662 [TBL] [Abstract][Full Text] [Related]
7. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. Dhanda DS; Tyagi P; Mirvish SS; Kompella UB J Control Release; 2013 Jun; 168(3):239-50. PubMed ID: 23562638 [TBL] [Abstract][Full Text] [Related]
8. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761 [TBL] [Abstract][Full Text] [Related]
10. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. Oh YJ; Lee J; Seo JY; Rhim T; Kim SH; Yoon HJ; Lee KY J Control Release; 2011 Feb; 150(1):56-62. PubMed ID: 21070826 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Meenach SA; Kim YJ; Kauffman KJ; Kanthamneni N; Bachelder EM; Ainslie KM Mol Pharm; 2012 Feb; 9(2):290-8. PubMed ID: 22149217 [TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891 [TBL] [Abstract][Full Text] [Related]
13. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. Ohashi K; Kabasawa T; Ozeki T; Okada H J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349 [TBL] [Abstract][Full Text] [Related]
15. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs. Patel B; Rashid J; Ahsan F Eur J Pharm Sci; 2017 Jan; 96():560-570. PubMed ID: 27989858 [TBL] [Abstract][Full Text] [Related]
16. Microsphere delivery of Risperidone as an alternative to combination therapy. D'Souza S; Faraj J; DeLuca P Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Dillen K; Vandervoort J; Van den Mooter G; Ludwig A Int J Pharm; 2006 May; 314(1):72-82. PubMed ID: 16600538 [TBL] [Abstract][Full Text] [Related]
18. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178 [TBL] [Abstract][Full Text] [Related]
19. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method. Choi SH; Park TG Int J Pharm; 2006 Mar; 311(1-2):223-8. PubMed ID: 16423477 [TBL] [Abstract][Full Text] [Related]
20. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Thote AJ; Gupta RB Nanomedicine; 2005 Mar; 1(1):85-90. PubMed ID: 17292062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]